Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: May, 2014 | Pages:
74 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)
Inovio Pharmaceuticals, Inc. - Product Pipeline Review - 2014 Summary Global Markets Direct's, 'Inovio Pharmaceuticals, Inc. - Product Pipeline Review - 2014', provides an overview of the Inovio Pharmaceuticals, Inc.'s pharmaceutical research and development focus. This report provides comprehensive information on the current therapeutic developmental pipeline of Inovio Pharmaceuticals, Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides brief overview of Inovio Pharmaceuticals, Inc. including business description, key information and facts, and its locations and subsidiaries - The report reviews current pipeline of Inovio Pharmaceuticals, Inc.'s human therapeutic division and enlists all their major and minor projects - The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones - Special feature on out-licensed and partnered product portfolio - The report summarizes all the dormant and discontinued pipeline projects - Latest company statement - Latest news and deals relating to the Inovio Pharmaceuticals, Inc.'s pipeline products Reasons to buy - Evaluate Inovio Pharmaceuticals, Inc.'s strategic position with total access to detailed information on its product pipeline - Assess the growth potential of Inovio Pharmaceuticals, Inc. in its therapy areas of focus - Identify new drug targets and therapeutic classes in the Inovio Pharmaceuticals, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas - Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps - Develop strategic initiatives by understanding the focus areas of Inovio Pharmaceuticals, Inc. and exploit collaboration and partnership opportunities - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Plan mergers and acquisitions effectively by identifying the most promising pipeline of Inovio Pharmaceuticals, Inc. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Explore the dormant and discontinued projects of Inovio Pharmaceuticals, Inc. and identify potential opportunities in those areas - Avoid Intellectual Property Rights related issues
Table of Contents Table of Contents 2 List of Tables 6 List of Figures 6 Inovio Pharmaceuticals, Inc. Snapshot 7 Inovio Pharmaceuticals, Inc. Overview 7 Key Information 7 Key Facts 7 Inovio Pharmaceuticals, Inc. - Research and Development Overview 8 Key Therapeutic Areas 8 Inovio Pharmaceuticals, Inc. - Pipeline Review 11 Pipeline Products by Stage of Development 11 Pipeline Products - Monotherapy 12 Pipeline Products - Combination Treatment Modalities 13 Pipeline Products - Partnered Products 14 Partnered Products/Combination Treatment Modalities 15 Pipeline Products - Out-Licensed Products 16 Out-Licensed Products/Combination Treatment Modalities 17 Inovio Pharmaceuticals, Inc. - Pipeline Products Glance 18 Inovio Pharmaceuticals, Inc. - Clinical Stage Pipeline Products 18 Phase II Products/Combination Treatment Modalities 18 Phase I Products/Combination Treatment Modalities 19 Inovio Pharmaceuticals, Inc. - Early Stage Pipeline Products 21 Preclinical Products/Combination Treatment Modalities 21 Inovio Pharmaceuticals, Inc. - Drug Profiles 23 VGX-3100 23 Product Description 23 Mechanism of Action 23 R&D Progress 23 H1N1 Syncon Universal Influenza Vaccine 24 Product Description 24 Mechanism of Action 24 R&D Progress 24 INO-3112 25 Product Description 25 Mechanism of Action 25 R&D Progress 25 INO-3401 26 Product Description 26 Mechanism of Action 26 R&D Progress 26 INO-3510 28 Product Description 28 Mechanism of Action 28 R&D Progress 28 INO-3605 30 Product Description 30 Mechanism of Action 30 R&D Progress 30 INO-3609 32 Product Description 32 Mechanism of Action 32 R&D Progress 32 INO-8000 34 Product Description 34 Mechanism of Action 34 R&D Progress 34 PENNVAX-B 35 Product Description 35 Mechanism of Action 35 R&D Progress 35 Pennvax-G 37 Product Description 37 Mechanism of Action 37 R&D Progress 37 VGX-1027 38 Product Description 38 Mechanism of Action 38 R&D Progress 38 VGX-3400X 39 Product Description 39 Mechanism of Action 39 R&D Progress 39 VRC-01 41 Product Description 41 Mechanism of Action 41 R&D Progress 41 DNA Vaccine for Chikungunya 43 Product Description 43 Mechanism of Action 43 R&D Progress 43 DNA Vaccine for H3N2 Influenza 44 Product Description 44 Mechanism of Action 44 R&D Progress 44 DNA Vaccine for H7N9 Universal Influenza 45 Product Description 45 Mechanism of Action 45 R&D Progress 45 DNA Vaccine for MERS Coronavirus Infection 46 Product Description 46 Mechanism of Action 46 R&D Progress 46 DNA Vaccine For Smallpox 47 Product Description 47 Mechanism of Action 47 R&D Progress 47 DNA-based IL-33 + HPV-16 DNA Vaccine 48 Product Description 48 Mechanism of Action 48 R&D Progress 48 INO-1400 49 Product Description 49 Mechanism of Action 49 R&D Progress 49 INO-7103 50 Product Description 50 Mechanism of Action 50 R&D Progress 50 INO-7105 52 Product Description 52 Mechanism of Action 52 R&D Progress 52 MAV-12 53 Product Description 53 Mechanism of Action 53 R&D Progress 53 Pennvax-GP 54 Product Description 54 Mechanism of Action 54 R&D Progress 54 Polyvalent DNA Vaccine for Ebola and Marburg Filoviruses 55 Product Description 55 Mechanism of Action 55 R&D Progress 55 Inovio Pharmaceuticals, Inc. - Pipeline Analysis 56 Inovio Pharmaceuticals, Inc. - Pipeline Products by Target 56 Inovio Pharmaceuticals, Inc. - Pipeline Products by Route of Administration 58 Inovio Pharmaceuticals, Inc. - Pipeline Products by Molecule Type 59 Inovio Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action 60 Inovio Pharmaceuticals, Inc. - Recent Pipeline Updates 61 Inovio Pharmaceuticals, Inc. - Dormant Projects 68 Inovio Pharmaceuticals, Inc. - Discontinued Pipeline Products 69 Discontinued Pipeline Product Profiles 69 mifepristone 69 VGX-410C 69 Inovio Pharmaceuticals, Inc. - Company Statement 70 Inovio Pharmaceuticals, Inc. - Locations And Subsidiaries 72 Head Office 72 Other Locations & Subsidiaries 72 Appendix 73 Methodology 73 Coverage 73 Secondary Research 73 Primary Research 73 Expert Panel Validation 73 Contact Us 74 Disclaimer 74
List of Tables Inovio Pharmaceuticals, Inc., Key Information 7 Inovio Pharmaceuticals, Inc., Key Facts 7 Inovio Pharmaceuticals, Inc. - Pipeline by Indication, 2014 9 Inovio Pharmaceuticals, Inc. - Pipeline by Stage of Development, 2014 11 Inovio Pharmaceuticals, Inc. - Monotherapy Products in Pipeline, 2014 12 Inovio Pharmaceuticals, Inc. - Combination Treatment Modalities in Pipeline, 2014 13 Inovio Pharmaceuticals, Inc. - Partnered Products in Pipeline, 2014 14 Inovio Pharmaceuticals, Inc. - Partnered Products/ Combination Treatment Modalities, 2014 15 Inovio Pharmaceuticals, Inc. - Out-Licensed Products in Pipeline, 2014 16 Inovio Pharmaceuticals, Inc. - Out-Licensed Products/ Combination Treatment Modalities, 2014 17 Inovio Pharmaceuticals, Inc. - Phase II, 2014 18 Inovio Pharmaceuticals, Inc. - Phase I, 2014 19 Inovio Pharmaceuticals, Inc. - Preclinical, 2014 21 Inovio Pharmaceuticals, Inc. - Pipeline by Target, 2014 57 Inovio Pharmaceuticals, Inc. - Pipeline by Route of Administration, 2014 58 Inovio Pharmaceuticals, Inc. - Pipeline by Molecule Type, 2014 59 Inovio Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action, 2014 60 Inovio Pharmaceuticals, Inc. - Recent Pipeline Updates, 2014 61 Inovio Pharmaceuticals, Inc. - Dormant Developmental Projects,2014 68 Inovio Pharmaceuticals, Inc. - Discontinued Pipeline Products, 2014 69 Inovio Pharmaceuticals, Inc., Subsidiaries 72
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
